Maxim Group Gives a Buy Rating to Sucampo Pharmaceuticals

By Ryan Adsit

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), with a price target of $21. The company’s shares opened today at $9.70.

Kolbert wrote:

“Summary Sucampo announced the publication of a new study in an independent scientific journal that confirms the unique composition of VTS-270, a 2-Hydroxypropyl- beta-cyclodextrin (HPβCD) product under investigation as a novel treatment for Niemann-Pick Disease Type C1 (NPC-1).”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -11.1% and a 31.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Sucampo Pharmaceuticals is Strong Buy and the average price target is $14, representing a 44.3% upside.

In a report issued on April 4, Mizuho Securities also reiterated a Buy rating on the stock with a $14 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company’s product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.